State of CBD Research in 2022

1 year ago

In 2021, the global CBD market was valued at US$4.20 billion. The market is projected to reach US$12.64 billion by 2026. The growing regulatory approvals is a major driver of the market. The CBD market is expected to grow at a CAGR of 25.53% during the forecast period of 2022-2026.

Since CBD has only recently entered the medical mainstream, there are still many unanswered questions to be explored. Early research focused on the role of cannabinoid receptors in the brain in perceiving and processing CBD, as well as its effect on the brain’s production of dopamine.

Over the last few years, doctors have launched small-scale CBD studies and CBD clinical trials to find other potential uses for the compound. CBD is gaining notoriety as a potential treatment for a variety of mood disorders, especially generalized anxiety. It may even help PTSD sufferers.

Naturally, there is still much to learn about CBD. No long-term (“longitudinal”) study has shown the effects of CBD on brain structure or quality of life. It will be some time before a large enough patient community exists for a multi-decade CBD clinical study to be completed.

Why do we need further studies?

The market is growing, user adoption is sky rocketing and consumers are making the switch to cannabinoid-based products for a wide variety of health concerns. When we have sufficient proof in the form of user buy-in, why then do we need further studies?

The fact of the matter is that CBD is a substance humans have been in contact with for centuries. However, we know relatively little about its potential applications in modern medicine. Much of the data that exists is for older patients and those who have suffered chronic conditions for many years.

Promising CBD medical discoveries point to the possibility that it might be useful for a wide range of conditions throughout life. The better doctors come to understand how CBD affects the perception of pain, the easier it will be to prescribe effective and safe doses.

CBD (Cannabidiol) Clinical Trials in 2022

The following are among the latest clinical trials being conducted around cannabidiol use for health and wellness. You can click through on these to read about their findings in more detail:

• CBD (Cannabidiol) Intraoral Application and TMD (Temporomandibular Disorders)
• Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
• The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence
• Epidiolex® for Anxiety in Pediatric Epilepsy
• Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients
• Reducing Pain and Opioid Use With CBD
• Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota
• Pharmacokinetic Investigation of BSPG Laboratories (BSPG) Cannabidiol in Healthy Participants
• Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
• The CANabidiol Use for RElief of Short Term Insomnia
• Cannabidiol and Focus Study (CBD-Focus)
• Evaluation of the Interactions of Cannabidiol (CBD) With Morphine

As time goes on, medical research into CBD is uncovering how to reduce side effects and ensure safety when CBD is used alongside conventional medication. In years to come, CBD may take a place as one of the most valuable treatments for childhood epilepsy, chronic pain, and even many treatment-resistant mood disorders experienced by millions of Americans.